294 related articles for article (PubMed ID: 25475894)
1. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
2. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
3. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
5. Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors.
Heider F; Ansideri F; Tesch R; Pantsar T; Haun U; Döring E; Kudolo M; Poso A; Albrecht W; Laufer SA; Koch P
Eur J Med Chem; 2019 Aug; 175():309-329. PubMed ID: 31096153
[TBL] [Abstract][Full Text] [Related]
6. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
Muth F; El-Gokha A; Ansideri F; Eitel M; Döring E; Sievers-Engler A; Lange A; Boeckler FM; Lämmerhofer M; Koch P; Laufer SA
J Med Chem; 2017 Jan; 60(2):594-607. PubMed ID: 27977190
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 2'-anilino-4,4'-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Xue Y; Arzel E; Kallin E; Magnus A; Plobeck N; Viklund J
Bioorg Med Chem Lett; 2006 Mar; 16(5):1397-401. PubMed ID: 16337120
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
10. 1-Aryl-3,4-dihydroisoquinoline inhibitors of JNK3.
Christopher JA; Atkinson FL; Bax BD; Brown MJ; Champigny AC; Chuang TT; Jones EJ; Mosley JE; Musgrave JR
Bioorg Med Chem Lett; 2009 Apr; 19(8):2230-4. PubMed ID: 19303774
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
[TBL] [Abstract][Full Text] [Related]
12. Unexpected reaction of 2-alkylsulfanylimidazoles to imidazol-2-ones: pyridinylimidazol-2-ones as novel potent p38alpha mitogen-activated protein kinase inhibitors.
Koch P; Laufer S
J Med Chem; 2010 Jun; 53(12):4798-802. PubMed ID: 20481631
[TBL] [Abstract][Full Text] [Related]
13. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
14. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
Kong TT; Zhang CM; Liu ZP
Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
[TBL] [Abstract][Full Text] [Related]
15. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.
Probst GD; Bowers S; Sealy JM; Truong AP; Hom RK; Galemmo RA; Konradi AW; Sham HL; Quincy DA; Pan H; Yao N; Lin M; Tóth G; Artis DR; Zmolek W; Wong K; Qin A; Lorentzen C; Nakamura DF; Quinn KP; Sauer JM; Powell K; Ruslim L; Wright S; Chereau D; Ren Z; Anderson JP; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2011 Jan; 21(1):315-9. PubMed ID: 21112785
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR studies of 1,2-diaryl-1H-benzimidazole derivatives as JNK3 inhibitors with protective effects in neuronal cells.
Kim MH; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2013 Mar; 23(6):1639-42. PubMed ID: 23416008
[TBL] [Abstract][Full Text] [Related]
17. Tri- and tetrasubstituted imidazoles as p38α mitogen-activated protein kinase inhibitors.
Laufer S; Hauser D; Stegmiller T; Bracht C; Ruff K; Schattel V; Albrecht W; Koch P
Bioorg Med Chem Lett; 2010 Nov; 20(22):6671-5. PubMed ID: 20934337
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
19. JNK3 as a therapeutic target for neurodegenerative diseases.
Antoniou X; Falconi M; Di Marino D; Borsello T
J Alzheimers Dis; 2011; 24(4):633-42. PubMed ID: 21321401
[TBL] [Abstract][Full Text] [Related]
20. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]